XTX Topco’s Cytokinetics CYTK Stock Holding History

XTX Topco’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.57M	Sell	23,853 -66,726	-74%	-$4.24M	0.03%	1038
2025 Q4	$5.76M	Buy	90,579 +86,589	+2,170%	+$5.39M	0.15%	97
2025 Q3	$219K	Buy	+3,990	New	+$164K	0.01%	1773
2025 Q2	–	Sell	-7,357	Closed	-$296K	–	2513
2025 Q1	$296K	Sell	7,357 -2,293	-24%	-$105K	0.02%	1416
2024 Q4	$454K	Sell	9,650 -221	-2%	-$11.5K	0.04%	852
2024 Q3	$521K	Buy	+9,871	New	+$550K	0.04%	788
2024 Q1	–	Sell	-4,178	Closed	-$349K	–	1928
2023 Q4	$349K	Sell	4,178 -14,418	-78%	-$522K	0.08%	505
2023 Q3	$548K	Buy	+18,596	New	+$619K	0.09%	341
2022 Q3	–	Sell	-16,811	Closed	-$661K	–	1150
2022 Q2	$661K	Buy	+16,811	New	+$677K	0.27%	74

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

XTX Topco's CYTK Position: Q1 2026 in Review

XTX Topco reduced its Cytokinetics (CYTK) stake by 74% in Q1 2026, selling an estimated $4.24M and leaving 23,853 shares worth $1.57M. The position accounts for 0.03% of the portfolio, ranked #1038.

XTX Topco first reported a position in CYTK in Q2 2022 and has held it in 9 quarters since. The position peaked at $5.76M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

XTX Topco held 23,853 shares of Cytokinetics worth $1.57M as of Q1 2026.
XTX Topco sold 66,726 Cytokinetics shares in Q1 2026, an estimated $4.24M.
Cytokinetics made up 0.03% of XTX Topco's portfolio in Q1 2026, its #1038 holding.
XTX Topco first reported a position in Cytokinetics in Q2 2022 and has held it in 9 quarters since.
XTX Topco's Cytokinetics position peaked at $5.76M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.